Home Topics Drug Discovery venBio Writes New Chapter with $550M Fourth Fund

venBio team — [L.-R.] venBio says its team will evaluate companies to be funded through its just-closed fourth life sciences fund of $550 million. Top row: Yvonne Yamanaka, PhD, Principal; Robert Adelman, MD, Managing Partner. Bottom row: Aaron Royston, MD, MBA, Managing Partner; Corey Goodman, PhD, Managing Partner; and Richard Gaster, MD, PhD, Managing Partner. [venBio]

venBio Writes New Chapter with $550M Fourth Fund

Veteran neuroscientist/entrepreneur Corey Goodman shares his VC firm’s approach to funding with GEN Edge

By Alex Philippidis

June 14, 2021

[L.-R.] venBio says its team will evaluate companies to be funded through its just-closed fourth life sciences fund of $550 million. Top row: Yvonne Yamanaka, PhD, Principal; Robert Adelman, MD, Managing Partner. Bottom row: Aaron Royston, MD, MBA, Managing Partner; Corey Goodman, PhD, Managing Partner; and Richard Gaster, MD, PhD, Managing Partner. [venBio]

Like the firm's three earlier funds, the new venBio Global Strategic Fund IV is expected to fund 12 to 15 companies, with each company typically receiving $30-40 million--though the firm has invested more in a few companies . . .